New ALS drug candidate QRL-101 tested in small safety trial
Disease control
Completed
This phase 1 study tested a single dose of the experimental drug QRL-101 in 12 people with ALS. The main goals were to see how the drug moves through the body and whether it is safe. Participants received either QRL-101 or a placebo, and researchers monitored side effects and dru…
Phase: PHASE1 • Sponsor: QurAlis Corporation • Aim: Disease control
Last updated Jun 26, 2026 13:14 UTC